Background: Bioengineering has come of ages by setting up spare parts manufacturing
units to be used in human body such as invasive implants and interventional controlled drug delivery
in vivo systems. As a matter of fact patients on basis of their fiscal strength have the option to undergo
prophylactic tactical manoeuvre for longer life spans. In this sphere of invasive implants, biocompatible
polymer implants are a state of the art cutting edge technology with outstanding innovations leading
to number of very successful start-up companies with a plethora of patent portfolios.
Objective: From 2000 onwards, patent filings and grants for biocompatible polymers are expanding.
Currently definition of biocompatibility is quite ambiguous with respect to the use of FDA approved
polymeric materials. This article analysed patent portfolios for the trend patterns of prolific biocompatible
polymers for capitalization and commercialization in the forthcoming years.
Method: Pair Bulk Data (PBD) portal was used to mine patent portfolios. In this patent preliminary
analysis report, patents from 2000 to 2015 were evaluated using 317(c) filings, grants and classifications
data for poly(vinyl alcohol) (PVA), poly(glycolic acid) (PGA), poly(hydroxyalkanoates) (PHAs)
and poly(lactic acid) (PLA).
Conclusion: This patent portfolio preliminary analysis embarks into patent analysis for New Product
Development (NPD) for corporate R&D investment managerial decisions and on government advocacy
for federal funding which is decisive for developmental advances. An in-depth patent portfolio
investigation with return of investment (RoI) is in the pipeline.